Kyverna Therapeutics, Inc. (KYTX)
| Market Cap | 347.08M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -75.92M |
| Shares Out | 43.12M |
| EPS (ttm) | -1.76 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 624,146 |
| Open | 7.75 |
| Previous Close | 7.81 |
| Day's Range | 7.68 - 8.31 |
| 52-Week Range | 6.75 - 30.60 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 39.50 (+390.68%) |
| Earnings Date | Aug 12, 2024 |
About KYTX
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for KYTX stock is "Buy." The 12-month stock price forecast is $39.5, which is an increase of 390.68% from the latest price.
News
The Schall Law Firm Is Conducting A Securities Fraud Investigation Into Kyverna Therapeutics Inc And Invites KYTX Shareholders To Participate
LOS ANGELES, CA / ACCESSWIRE / July 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive,...
Kyverna Therapeutics Inc And KYTX Stock Proprietors Are Welcomed To Engage In A Securities Fraud Examination Performed By The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / July 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive,...
Kyverna Therapeutics Inc And KYTX Stock Possessors Are Requested To Be Part Of A Securities Fraud Inquiry Carried Out By The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / June 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive...
Kyverna Therapeutics Inc And KYTX Stock Holders Are Invited To Join A Securities Fraud Probe Conducted By The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / June 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive...
Kyverna Therapeutics Inc And KYTX Shareholders Are Invited To Be Involved In A Securities Fraud Probe Conducted By The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / June 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive...
The Schall Law Firm Is Undertaking A Securities Fraud Probe Into Kyverna Therapeutics Inc And Encourages KYTX Shareholders To Join
LOS ANGELES, CA / ACCESSWIRE / June 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive...
Kyverna Therapeutics Inc And KYTX Stock Owners Are Encouraged To Participate In A Securities Fraud Investigation Led By The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive...
The Schall Law Firm Is Conducting A Securities Fraud Investigation Into Kyverna Therapeutics Inc And Invites KYTX Shareholders To Participate
LOS ANGELES, CA / ACCESSWIRE / June 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive...
KYTX Shareholders Have The Opportunity To Participate In The Securities Fraud Investigation Of Kyverna Therapeutics Inc Led By The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / June 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive...
The Schall Law Firm Is Conducting A Securities Fraud Probe Into Kyverna Therapeutics Inc And KYTX Shareholders Are Invited To Be Involved
LOS ANGELES, CA / ACCESSWIRE / June 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive...
KYTX Shareholders Can Join The Securities Fraud Investigation Of Kyverna Therapeutics Inc Conducted By The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / June 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive...
Shareholders Of KYTX Have The Opportunity To Participate In The Securities Fraud Scrutiny Of Kyverna Therapeutics Inc Led By The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / June 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive...
Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial
This IND clearance expands the use of KYV-101 CAR T-cell therapy in a Phase 2, open-label KYSA-8 clinical trial targeting a devastating neuroimmunological autoimmune disease KYV-101 is a fully human a...
Investors Of KYTX Can Join The Securities Fraud Investigation Of Kyverna Therapeutics Inc Conducted By The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / June 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive...
KYTX Investors Can Join The Securities Fraud Investigation Of Kyverna Therapeutics Inc By Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / June 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive...
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS)
Patient received KYV-101, a fully human anti-CD19 CAR T-cell product candidate, as part of a named-patient treatment option after failure to respond to conventional therapies Significant improvement i...
Investors In KYTX Have The Chance To Participate In The Securities Fraud Probe Against Kyverna Therapeutics, Inc. With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / June 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive...
KYTX Investors Have Opportunity to Join Kyverna Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--KYTX Investors Have Opportunity to Join Kyverna Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm.
Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology
Promising results from early clinical experience with anti-CD19 CAR T cells in patients with autoimmune diseases Optimal CAR construct design contributing to an acceptable safety profile, and potentia...
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
Advanced clinical development in two broad areas of autoimmune disease: rheumatology and neurology Treated 30 patients cumulatively as of May 14, 2024, including eight patients with myasthenia gravis,...
Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases
Poster #14-006 describes the first successful treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR-T cells Kyverna to host a conference ca...
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med
Two patients were treated with KYV-101, a fully human anti-CD19 CAR T-cell product candidate, in Germany as part of a named patient program after failure to respond to conventional therapies The treat...
Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results
Advanced clinical development in two broad areas of autoimmune disease: rheumatology and neurology Strong balance sheet, bolstered by recent public offering, expected to fund operations into 2026 EMER...
Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis
The Investigator-Initiated Trial will assess the safety, tolerability, and clinical activity of KYV-101, a fully human anti CD19 CAR T-cell therapy in up to 12 study participants The clinical study wi...
Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
EMERYVILLE, Calif. , Feb. 12, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients s...